Betaseron is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, Albumin (Human), USP, or any other component of the formulation.
DRUG ABUSE AND DEPENDENCE
No evidence or experience suggests that abuse or dependence occurs with Betaseron therapy; however, the risk of dependence has not been systematically evaluated.
1 Poser CM, et al. Ann Neurol 1983; 13(3): 227-231
2 Kurtzke JF. Neurology 1983; 33(11): 1444-1452
U.S. Patent No. 4,588,585; 4,961,969; 5,702,699; 6,994,847